Skip to main content
Equibles
NMTC logo

NMTC · NEUROONE MEDICAL TECHNOLOGIES Corp · Metrics

Track NMTC — free

Use NMTC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NMTC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.97 +0.11 (+12.96%) At close · Oct 29 Q3 2026 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$7.82M
Shares
9.11M
Volume · Oct 29 66.81K Avg daily vol (3M) 342.04K

NMTC metrics

82 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.97
Market cap
$7.82M

Price action

20 metrics
Price change (1W)
-5.8%
Price change (30D)
-21.2%
Price change (3M)
-48.0%
Price change (6M)
-81.7%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
81.4%
Annualized volatility (3M)
94.5%
Beta
1.0
RSI (14D)
32.8
Price vs SMA 50
-37.4%
Price vs SMA 200
—
Avg volume (3M)
341,533
Relative volume
0.1
Average dollar volume
$599,658

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
9.11M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.6×
reciprocal yield 166.4%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.8×
reciprocal yield 122.4%
P / book
2.1
reciprocal yield 48.7%
FCF yield
-92.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-96.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
5.2×
reciprocal yield 19.3%
EV / revenue historical average (5Y)
5.2×
reciprocal yield 19.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-13

Profitability

9 metrics
Gross margin
55.6%
Operating margin
-83.4%
Trailing 12 months
Net margin
-78.6%
Gross profit (TTM)
$5.27M
Operating profit (TTM)
−$7.90M
Net income (TTM)
−$7.45M
Trailing 12 months
Diluted EPS (TTM)
$-1.01
FCF margin
-75.6%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$1.12
Gross profit per diluted share (TTM)
$0.62
Operating profit per diluted share (TTM)
$-0.93
EBITDA per diluted share (TTM)
$-0.90
Net income per diluted share (TTM)
$-0.88
Operating cash flow per diluted share (TTM)
$-0.84
Free cash flow per diluted share (TTM)
$-0.85
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$0.64
Stock compensation per diluted share (TTM)
$0.17
Book value per share
$0.85

Growth

11 metrics
Revenue growth YoY
+16.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$9.47M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+7.9%
Year over year · more shares
Revenue CAGR (3Y)
+276.0%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-197.6%
Return on assets
-120.4%
Debt / equity
0.0
Current ratio
2.8
EBITDA (TTM)
−$7.66M
Free cash flow (TTM)
−$7.16M
Quick ratio
1.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$2.05M
Latest balance sheet
Cash & equivalents
$2.05M
Total assets
$6.19M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$7.05M
Capital expenditures (TTM)
$109,536
R&D (TTM)
$5.40M
SG&A (TTM)
$7.77M
Stock compensation (TTM)
$1.41M
R&D / revenue
57.0%
Stock compensation / revenue
14.9%

Ownership (13F)

9 metrics
13F filers
26
13F filer change QoQ
-7
Institutional ownership
22.4%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
13.1%
Private-fund adviser ownership
12.2%
Active holders' share change QoQ
-3.1%
Holder tenure
5.0
Price vs estimated holder cost
-23.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
5.0%

Short interest

3 metrics
Short interest
2.3%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
43 / 100

Insider activity

2 metrics
Net insider buying (90D)
$66,999
Insider-sentiment score
83 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1500198 CUSIP 64130M308 13F (30d) 3 filings 3 filers Visit website Investor relations